BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
1.340
+0.080 (6.35%)
Oct 31, 2025, 12:48 PM EDT - Market open
BioCardia Revenue
In the year 2024, BioCardia had annual revenue of $58.00K, down -87.84%.
Revenue (ttm)
$58.00K
Revenue Growth
-87.84%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
14.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 58.00K | -419.00K | -87.84% |
| Dec 31, 2023 | 477.00K | -875.00K | -64.72% |
| Dec 31, 2022 | 1.35M | 337.00K | 33.20% |
| Dec 31, 2021 | 1.02M | 870.00K | 600.00% |
| Dec 31, 2020 | 145.00K | -565.00K | -79.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
BCDA News
- 4 weeks ago - BioCardia Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 6 weeks ago - BioCardia Announces Pricing of Up To $12 Million Public Offering - GlobeNewsWire
- 6 weeks ago - BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up - GlobeNewsWire
- 2 months ago - BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025 - GlobeNewsWire
- 2 months ago - BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 3 months ago - BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 - GlobeNewsWire
- 3 months ago - BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter - GlobeNewsWire